Simcha Therapeutics Accelerates Growth with Key Leadership Appointments, Expanded Research and Option Agreement with Yale School of Medicine
Retrieved on:
Tuesday, August 16, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Sequah Medicine Company, LIFE, Beatrice, Thomas Jefferson University, ATyr Pharma, CEO, Internal medicine, Wuxi, Cancer, SVKM's NMIMS, Thomas Jefferson University Hospital, Yale School of Medicine, Research, Kellogg School, Patient, Therapy, Company, Amgen, Skin, Bauer, PPD, Cytokine, Iron ring (laboratory), Radius Ventures, Organization, RNA transfection, Management, Pharmaceutical industry, Simcha, Medicine, Pfizer, Northwestern University
Simcha has also expanded its sponsored research agreement with Yale School of Medicine related to cytokine biology in the laboratory of Aaron Ring, Ph.D., M.D., associate professor of immunobiology and Simcha founder.
Key Points:
- Simcha has also expanded its sponsored research agreement with Yale School of Medicine related to cytokine biology in the laboratory of Aaron Ring, Ph.D., M.D., associate professor of immunobiology and Simcha founder.
- Through this expanded agreement, the company will support research in the Ring Laboratory focused on overcoming biological limitations of native cytokines.
- Simcha holds an exclusive option to license multiple therapeutic agents resulting from the expanded research agreement.
- Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients.